title: New formulation of chemical peeling agent: 30% salicylic acid in polyethylene glycol. Absorption and distribution of 14C-salicylic acid in polyethylene glycol applied topically to skin of hairless mice.
abstract: Salicylic acid is used in chemical peeling procedures. However, they have caused many side effects, even salicylism. To achieve a salicylic acid peeling that would be safer for topical use, we recently developed a new formulation consisting of 30% salicylic acid in polyethylene glycol (PEG) vehicle. In an extension of our previous research, we studied the absorption of 30% salicylic acid labeled with 14C in PEG vehicle applied topically to the intact and damaged skin of male hairless mice. An ointment containing 3 mg salicylic acid in 10 mg vehicle was applied to both groups. In animals with intact skin, 1 h after application the plasma concentration of radioactivity was 1665.1 ng eq/ml, significantly lower than the 21437.6 ng eq/ml observed in mice with damaged skin. Microautoradiograms of intact skin showed that the level of radioactivity in the cornified cell layer was similar at 6 h after application. However, in damaged skin, the overall level of radioactivity showed a decrease by 3 h after application. In the carcasses remaining after the treated intact and damaged skin had been removed, 0.09 and 11.38% of the applied radioactivity remained, respectively. These findings confirm that 30% salicylic acid in PEG vehicle is little absorbed through the intact skin of hairless mice, and suggest that salicylism related to absorption through the skin of quantities of topically applied salicylic acid is not likely to occur in humans with intact skin during chemical peeling with this preparation. This new preparation of 30% salicylic acid in PEG vehicle is believed to be safe for application as a chemical peeling agent.
authors.affiliation: Ueda Setsuko Clinic, 2-1-1 Chihaya, Higashiku, Fukuoka, Japan. setuueda@po.iijnet.or.jp
authors.forename: Setsuko
authors.initials: S
authors.lastname: Ueda
authors.forename: Koichi
authors.initials: K
authors.lastname: Mitsugi
authors.forename: Kazumi
authors.initials: K
authors.lastname: Ichige
authors.forename: Kenji
authors.initials: K
authors.lastname: Yoshida
authors.forename: Tomoko
authors.initials: T
authors.lastname: Sakuma
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Ninomiya
authors.forename: Tetsuji
authors.initials: T
authors.lastname: Sudou
mesh_terms: D000042:Absorption; D000287:Administration, Topical; D000818:Animals; D001345:Autoradiography; D002250:Carbon Radioisotopes; D002626:Chemistry, Pharmaceutical; D004305:Dose-Response Relationship, Drug; D005079:Excipients; D008297:Male; D051379:Mice; D008819:Mice, Nude; D011092:Polyethylene Glycols; D020156:Salicylic Acid / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D012867:Skin / Q000378:metabolism*; D014018:Tissue Distribution
chemical_list: D002250:Carbon Radioisotopes; D005079:Excipients; D011092:Polyethylene Glycols; D020156:Salicylic Acid